In the ARISTOTLE trial, did the addition of irinotecan to neoadjuvant chemoradiation improve response rate or survival outcomes for locally advanced rectal cancer?
In the DBCG Skagen Trial 1, did hypopractionated regional nodal irradiation increase the risk of locoregional recurrence at 5 years?
Did total neoadjuvant therapy improve overall survival in the TNTCRT trial?
Does the addition of radium-223 improve outcomes for patients with renal cell carcinoma bone metastases?
Answers
No. It didn’t improve DFS and it reduced the proportion of patients who completed radiation.
No. It was 2.5% v 2.9% with 50 Gy in 25 fractions, and there was no increase in the rate of lymphedema at 3 years.
No, but it did improve the primary endpoint of DFS. Unique to this trial’s approach was the interdigitation of long course radiation with 6 cycles of capecitabine and oxaliplatin.
No. In the RADICAL trial, adding radium-223 did not decrease the risk of symptomatic skeletal events. | QuadShot News
In the DBCG Skagen Trial 1, did hypopractionated regional nodal irradiation increase the risk of locoregional recurrence at 5 years?
Did total neoadjuvant therapy improve overall survival in the TNTCRT trial?
Does the addition of radium-223 improve outcomes for patients with renal cell carcinoma bone metastases?
Answers
No. It didn’t improve DFS and it reduced the proportion of patients who completed radiation.
No. It was 2.5% v 2.9% with 50 Gy in 25 fractions, and there was no increase in the rate of lymphedema at 3 years.
No, but it did improve the primary endpoint of DFS. Unique to this trial’s approach was the interdigitation of long course radiation with 6 cycles of capecitabine and oxaliplatin.
No. In the RADICAL trial, adding radium-223 did not decrease the risk of symptomatic skeletal events. | QuadShot News